An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Colorectal Cancer (CRONOS 1)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01277120
First received: January 13, 2011
Last updated: July 7, 2014
Last verified: July 2014

January 13, 2011
July 7, 2014
April 2010
September 2014   (final data collection date for primary outcome measure)
Correlation of the time from the start of chemotherapy to the start of Avastin treatment with progression-free survival [ Time Frame: 60 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01277120 on ClinicalTrials.gov Archive Site
  • Overall survival [ Time Frame: 60 months ] [ Designated as safety issue: No ]
  • Safety: Incidence of adverse events [ Time Frame: 60 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Colorectal Cancer (CRONOS 1)
The Correlation Between the Moment of Bevacizumab theRapy initiatiOn and the Efficacy in patieNt With cOlorectal Cancer Treated With AvaStin Based First Line Regimens (CRONOS 1)

This single arm, prospective, observational study will assess the correlation be tween the time from start of chemotherapy to the start of Avastin (bevacizumab) treatment with progression-free survival in patients with previously untreated m etastatic colorectal cancer. Patients will be followed for up to 12 months after progressive disease occurs.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

First-line treatment with Avastin

Colorectal Cancer
Not Provided
Cohort
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
150
September 2014
September 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients, >/= the 18 years of age
  • Previously untreated metastatic colorectal cancer
  • Scheduled to start 1st line chemotherapeutic treatment
  • ECOG performance status 0-1

Exclusion Criteria:

  • Any conditions included in contraindication list for Avastin
  • Prior chemotherapy for metastatic colorectal cancer
  • Adjuvant/neoadjuvant chemotherapy or radio-chemotherapy of non-metastatic colorectal cancer completed <6 months prior to treatment start
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Romania
 
NCT01277120
ML25178
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP